Skip to content

Study · Systematic review · 2026

10 results

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.

Ciudin A, Johansson E, Zimner-Rapuch S, Dimitriadis GK, Hempfling M, Clark LJ, Fan L, Sapin H

Diabetes, obesity & metabolism28 Apr 2026

PMID42050884 (opens in a new tab)PMCIDPMC13243967 (opens in a new tab)DOI10.1111/dom.70773 (opens in a new tab)PepBankPUB-42050884
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with obesity, indirect comparison showed tirzepatide 10 mg reduced weight more than oral semaglutide 50 mg.

    In plain wordsIn adults with obesity, tirzepatide 10 mg led to more weight loss than oral semaglutide 50 mg in an indirect comparison.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight change versus oral semaglutide
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 50 mg (indirect, ML-NMR)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg · injectable · 72 weeksAs given in this study (human).

    Measurements

    Weight mean difference
    −4.48%
    tirzepatide 10 mg vs oral semaglutide

    Source sentences

    Summary
    Tirzepatide 10 and 15 mg were associated with statistically significantly greater reductions in weight (mean difference: -4.48% [-6.35, -2.61] and -5.59% [-7.52, -3.77])
    2 context sentences
    Summary · context
    Pivotal trials SURMOUNT-1 (tirzepatide, Week 72) and OASIS 1 (oral semaglutide, Week 68) were compared using multilevel network meta-regression (ML-NMR) to adjust for differences in sex, ethnicity and outcome baselines between trial populations.
    Summary · context
    Participants were adults without type 2 diabetes and with obesity (BMI ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) with ≥ 1 obesity-related complication.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with obesity, indirect comparison showed tirzepatide 15 mg reduced weight more than oral semaglutide 50 mg.

    In plain wordsIn adults with obesity, tirzepatide 15 mg led to more weight loss than oral semaglutide 50 mg in an indirect comparison.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight change versus oral semaglutide
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 50 mg (indirect, ML-NMR)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mg · injectable · 72 weeksAs given in this study (human).

    Measurements

    Weight mean difference
    −5.59%
    tirzepatide 15 mg vs oral semaglutide

    Source sentences

    Summary
    Tirzepatide 10 and 15 mg were associated with statistically significantly greater reductions in weight (mean difference: -4.48% [-6.35, -2.61] and -5.59% [-7.52, -3.77])
    2 context sentences
    Summary · context
    Pivotal trials SURMOUNT-1 (tirzepatide, Week 72) and OASIS 1 (oral semaglutide, Week 68) were compared using multilevel network meta-regression (ML-NMR) to adjust for differences in sex, ethnicity and outcome baselines between trial populations.
    Summary · context
    Participants were adults without type 2 diabetes and with obesity (BMI ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) with ≥ 1 obesity-related complication.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with obesity, indirect comparison showed tirzepatide 10 mg reduced waist circumference more than oral semaglutide 50 mg.

    In plain wordsIn adults with obesity, tirzepatide 10 mg reduced waist size more than oral semaglutide 50 mg in an indirect comparison.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWaist circumference change versus oral semaglutide
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 50 mg (indirect, ML-NMR)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg · injectable · 72 weeksAs given in this study (human).

    Measurements

    Waist circumference mean difference
    −3.6 cm
    tirzepatide 10 mg vs oral semaglutide

    Source sentences

    Summary
    Tirzepatide 10 and 15 mg were associated with statistically significantly greater reductions in weight (mean difference: -4.48% [-6.35, -2.61] and -5.59% [-7.52, -3.77]) and waist circumference (-3.60 cm [-5.59, -1.72] and -4.32 cm [-6.30, -2.40])
    2 context sentences
    Summary · context
    Pivotal trials SURMOUNT-1 (tirzepatide, Week 72) and OASIS 1 (oral semaglutide, Week 68) were compared using multilevel network meta-regression (ML-NMR) to adjust for differences in sex, ethnicity and outcome baselines between trial populations.
    Summary · context
    Participants were adults without type 2 diabetes and with obesity (BMI ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) with ≥ 1 obesity-related complication.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with obesity, indirect comparison showed tirzepatide 15 mg reduced waist circumference more than oral semaglutide 50 mg.

    In plain wordsIn adults with obesity, tirzepatide 15 mg reduced waist size more than oral semaglutide 50 mg in an indirect comparison.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWaist circumference change versus oral semaglutide
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 50 mg (indirect, ML-NMR)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mg · injectable · 72 weeksAs given in this study (human).

    Measurements

    Waist circumference mean difference
    −4.32 cm
    tirzepatide 15 mg vs oral semaglutide

    Source sentences

    Summary
    Tirzepatide 10 and 15 mg were associated with statistically significantly greater reductions in weight (mean difference: -4.48% [-6.35, -2.61] and -5.59% [-7.52, -3.77]) and waist circumference (-3.60 cm [-5.59, -1.72] and -4.32 cm [-6.30, -2.40])
    2 context sentences
    Summary · context
    Pivotal trials SURMOUNT-1 (tirzepatide, Week 72) and OASIS 1 (oral semaglutide, Week 68) were compared using multilevel network meta-regression (ML-NMR) to adjust for differences in sex, ethnicity and outcome baselines between trial populations.
    Summary · context
    Participants were adults without type 2 diabetes and with obesity (BMI ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) with ≥ 1 obesity-related complication.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with obesity, indirect comparison showed tirzepatide 10 and 15 mg gave higher odds of reaching 5%, 10%, 15% and 20% weight reduction than oral semaglutide 50 mg.

    In plain wordsIn adults with obesity, tirzepatide 10 and 15 mg made larger weight losses more likely than oral semaglutide 50 mg in an indirect comparison.

    Peptide
    Tirzepatide
    Outcome
    IncreaseOdds of 5%, 10%, 15% and 20% weight reduction versus oral semaglutide
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 50 mg (indirect, ML-NMR)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 and 15 mg · injectable · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide 10 and 15 mg were associated with statistically significantly greater reductions in weight (mean difference: -4.48% [-6.35, -2.61] and -5.59% [-7.52, -3.77]) and waist circumference (-3.60 cm [-5.59, -1.72] and -4.32 cm [-6.30, -2.40]), and higher odds of achieving ≥ 5%/10%/15%/20% weigh…
    2 context sentences
    Summary · context
    Pivotal trials SURMOUNT-1 (tirzepatide, Week 72) and OASIS 1 (oral semaglutide, Week 68) were compared using multilevel network meta-regression (ML-NMR) to adjust for differences in sex, ethnicity and outcome baselines between trial populations.
    Summary · context
    Participants were adults without type 2 diabetes and with obesity (BMI ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) with ≥ 1 obesity-related complication.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with obesity, cardiometabolic benefits were improved or generally comparable for tirzepatide versus oral semaglutide in an indirect comparison.

    In plain wordsIn adults with obesity, heart and metabolic benefits were better or about the same for tirzepatide compared with oral semaglutide.

    Peptide
    Tirzepatide
    Outcome
    MixedCardiometabolic benefits versus oral semaglutide
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 50 mg (indirect, ML-NMR)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · injectable · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Cardiometabolic benefits and safety profiles were improved or generally comparable for tirzepatide versus oral semaglutide.
    2 context sentences
    Summary · context
    Pivotal trials SURMOUNT-1 (tirzepatide, Week 72) and OASIS 1 (oral semaglutide, Week 68) were compared using multilevel network meta-regression (ML-NMR) to adjust for differences in sex, ethnicity and outcome baselines between trial populations.
    Summary · context
    Participants were adults without type 2 diabetes and with obesity (BMI ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) with ≥ 1 obesity-related complication.
  7. 07HumanSystematic reviewSafety outcome

    In adults with obesity, safety profiles were improved or generally comparable for tirzepatide versus oral semaglutide in an indirect comparison.

    In plain wordsIn adults with obesity, safety was better or about the same for tirzepatide compared with oral semaglutide.

    Peptide
    Tirzepatide
    Outcome
    MixedSafety profile versus oral semaglutide
    Study

    n: not reported in source

    Comparator
    Oral semaglutide 50 mg (indirect, ML-NMR)
    Outcome group
    Adverse events · Whole body
    Studied dose
    5, 10 and 15 mg · injectable · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Cardiometabolic benefits and safety profiles were improved or generally comparable for tirzepatide versus oral semaglutide.
    2 context sentences
    Summary · context
    Pivotal trials SURMOUNT-1 (tirzepatide, Week 72) and OASIS 1 (oral semaglutide, Week 68) were compared using multilevel network meta-regression (ML-NMR) to adjust for differences in sex, ethnicity and outcome baselines between trial populations.
    Summary · context
    Participants were adults without type 2 diabetes and with obesity (BMI ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) with ≥ 1 obesity-related complication.
  8. 08HumanSystematic reviewEfficacy outcome

    In adults with obesity, indirect comparison showed oral semaglutide 50 mg reduced weight less than tirzepatide 10 and 15 mg.

    In plain wordsIn adults with obesity, oral semaglutide 50 mg led to less weight loss than tirzepatide 10 and 15 mg in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight change versus tirzepatide
    Study

    n: not reported in source

    Comparator
    Tirzepatide 5, 10 and 15 mg (indirect, ML-NMR)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    50 mg · oral · 68 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide 10 and 15 mg were associated with statistically significantly greater reductions in weight (mean difference: -4.48% [-6.35, -2.61] and -5.59% [-7.52, -3.77])
    2 context sentences
    Summary · context
    Pivotal trials SURMOUNT-1 (tirzepatide, Week 72) and OASIS 1 (oral semaglutide, Week 68) were compared using multilevel network meta-regression (ML-NMR) to adjust for differences in sex, ethnicity and outcome baselines between trial populations.
    Summary · context
    Participants were adults without type 2 diabetes and with obesity (BMI ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) with ≥ 1 obesity-related complication.
  9. 09HumanSystematic reviewEfficacy outcome

    In adults with obesity, indirect comparison showed oral semaglutide 50 mg reduced waist circumference less than tirzepatide 10 and 15 mg.

    In plain wordsIn adults with obesity, oral semaglutide 50 mg reduced waist size less than tirzepatide 10 and 15 mg in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    IncreaseWaist circumference change versus tirzepatide
    Study

    n: not reported in source

    Comparator
    Tirzepatide 5, 10 and 15 mg (indirect, ML-NMR)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    50 mg · oral · 68 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide 10 and 15 mg were associated with statistically significantly greater reductions in weight (mean difference: -4.48% [-6.35, -2.61] and -5.59% [-7.52, -3.77]) and waist circumference (-3.60 cm [-5.59, -1.72] and -4.32 cm [-6.30, -2.40])
    2 context sentences
    Summary · context
    Pivotal trials SURMOUNT-1 (tirzepatide, Week 72) and OASIS 1 (oral semaglutide, Week 68) were compared using multilevel network meta-regression (ML-NMR) to adjust for differences in sex, ethnicity and outcome baselines between trial populations.
    Summary · context
    Participants were adults without type 2 diabetes and with obesity (BMI ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) with ≥ 1 obesity-related complication.
  10. 10HumanSystematic reviewEfficacy outcome

    In adults with obesity, indirect comparison showed lower odds of reaching 5%, 10%, 15% and 20% weight reduction with oral semaglutide 50 mg than with tirzepatide 10 and 15 mg.

    In plain wordsIn adults with obesity, oral semaglutide 50 mg made larger weight losses less likely than tirzepatide 10 and 15 mg in an indirect comparison.

    Peptide
    Semaglutide
    Outcome
    DecreaseOdds of 5%, 10%, 15% and 20% weight reduction versus tirzepatide
    Study

    n: not reported in source

    Comparator
    Tirzepatide 10 and 15 mg (indirect, ML-NMR)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    50 mg · oral · 68 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide 10 and 15 mg were associated with statistically significantly greater reductions in weight (mean difference: -4.48% [-6.35, -2.61] and -5.59% [-7.52, -3.77]) and waist circumference (-3.60 cm [-5.59, -1.72] and -4.32 cm [-6.30, -2.40]), and higher odds of achieving ≥ 5%/10%/15%/20% weigh…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.